AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Chairman’s report (verbal update)

5. Minutes of previous meeting
   - Matters arising

6. Appraisal 1 – alemtuzumab (MabCampath®)
   Treatment of B-cell chronic lymphocytic leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate

7. Appraisal 2 – atazanavir (Reyataz®) experienced adults
   Treatment of human immunodeficiency virus (HIV)-1 infected, antiretroviral treatment experienced adults, in combination with other antiretroviral medicinal products

8. Appraisal 3 – atazanavir (Reyataz®) naïve adults
   Antiretroviral treatment in naïve patients

9. Appraisal 4 – ambrisentan (Volibris®)
   Treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional Class II and III, to improve exercise capacity, decrease the symptoms of PAH and delay clinical worsening

10. AWMSG 2002-2008

11. Prioritisation of the AWMSG Medicines Strategy recommendations

12. Update on NHS Industry Forum
   - Draft minutes of October meeting

13. Update on AWPAG
   - Draft minutes of October meeting
   - Update of statin template

14. BNF Chapter 1 – Gastro-intestinal: Key Messages

15. Saving 1000 Lives Campaign

16. Welsh Analytical Prescribing Unit (verbal update)

17. Papers supplied by Welsh Assembly Government to AWMSG for information or comment:
   - Emergency oxygen use in Adults – British Thoracic Society guidance (for information)
Proposed Medicines Management Target for the Draft Service and Financial Framework Target

Date of next AWMSG meeting:
Wednesday, 25\textsuperscript{th} February 2009 at The Angel Hotel Abergavenny